Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 0.57 |
| ▸ | NFATC1 | O95644 | 5/20 | 0.57 |
| ▸ | GSK3B | P49841 | 4/20 | 0.57 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.48 |
| ▸ | CLK1 | P49759 | 5/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925138 | 0.81 | DYRK1A (0.59) | DYRK1ANFATC1GSK3BCDK2DYRK1B | |
| SCHEMBL24839617 | 0.78 | CLK1 (0.49) | CDK2CLK1CDK5CDK5R1MAP3K14 | |
| SCHEMBL3658484 | 0.73 | DYRK1A (1.00) | DYRK1ANFATC1GSK3BCDK2DYRK1B | |
| SCHEMBL3221770 | 0.73 | DYRK1A (0.51) | DYRK1ANFATC1GSK3BCDK2DYRK1B | |
| SCHEMBL25598680 | 0.71 | CCNT1 (0.60) | CDK2CLK1CDK5CDK5R1 | |
| SCHEMBL15648351 | 0.69 | CDK2 (0.55) | CDK2CLK1CDK5CDK5R1 | |
| SCHEMBL26725844 | 0.69 | DYRK1A (0.59) | DYRK1ANFATC1GSK3BCDK2DYRK1B | |
| SCHEMBL3658049 | 0.68 | PDPK1 (0.65) | DYRK1ANFATC1GSK3BCDK2DYRK1B | |
| SCHEMBL29488123 | 0.67 | CLK1 (0.71) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL16075920 | 0.67 | CLK1 (0.71) | DYRK1AGSK3BCLK1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT3A, CTNNB1, WNT1 | DYRK1A 1171/4885NFATC1 460/4885GSK3B 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.